155
Participants
Start Date
May 1, 2024
Primary Completion Date
April 7, 2027
Study Completion Date
April 7, 2029
YL211
Patients will be treated with YL211 intravenous (IV) infusion.
RECRUITING
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
RECRUITING
NEXT Oncology - Dallas, Irving
RECRUITING
The University of Texas - MD Anderson Cancer Center, Houston
RECRUITING
NEXT San Antonio, San Antonio
NOT_YET_RECRUITING
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
RECRUITING
Sarah Cannon Research Institute (SCRI) at HealthONE, Denver
RECRUITING
Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven, North Haven
RECRUITING
Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office, Sarasota
RECRUITING
Monash Health, Melbourne
RECRUITING
Princess Margaret Hospital, Toronto
NOT_YET_RECRUITING
The Ottawa Hospital - General Campus, Ottawa
NOT_YET_RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
Hoffmann-La Roche
INDUSTRY
MediLink Therapeutics (Suzhou) Co., Ltd.
INDUSTRY